Abstract
Background
Optic Pathway Gliomas (OPG) are the most common brain tumor in Neurofibromatosis 1 patients (NF1). They are found along the optic pathway and may involve the optic nerves, chiasm, retro-chiasmatic structures, and the optic radiations. NF1 associate OPG (NF1-OPG) have variable presentation, disease course and response to treatment. The optimal management is patient-specific and should be tailored by a multidisciplinary team. Age, sex, histology, and molecular markers may be important factors in the individualized decision-making process. Chemotherapy is the first-line treatment in cases of progressive tumors, and visual preservation is the main goal of treatment.
Purpose
In this paper we will review the disease, practical management, and recent advances of NF1-OPG.
Similar content being viewed by others
References
Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23:E3
Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53:1231–1237. https://doi.org/10.1002/pbc.22198
Grill J, Laithier V, Rodriguez D et al (2000) When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159:692–696
Tow SL, Chandela S, Miller NR, Avellino AM (2003) Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 28:262–270
Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111:568–577
Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189–198
Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D’Agostino McGowan L, Liu GT (2014) Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol 75:799–800. https://doi.org/10.1002/ana.24157
McClatchey AI (2007) Neurofibromatosis. Annu Rev Pathol 2:191–216. https://doi.org/10.1146/annurev.pathol.2.010506.091940
Czyzyk E, Jozwiak S, Roszkowski M, Schwartz RA (2003) Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 18:471–478
Blanchard G, Lafforgue M-P, Lion-François L, Kemlin I, Rodriguez D, Castelnau P, Carneiro M, Meyer P, Rivier F, Barbarot S, Chaix Y, NF France network (2016) Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 20:275–281. https://doi.org/10.1016/j.ejpn.2015.12.002
Listernick R, Charrow J, Greenwald M, Mets M (1994) Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 125:63–66. https://doi.org/10.1016/s0022-3476(94)70122-9
Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet A 127A:224–229. https://doi.org/10.1002/ajmg.a.20650
Chateil JF, Soussotte C, Pedespan JM et al (2001) MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 74:24–31
Hernaiz Driever P, von Hornstein S, Pietsch T et al (2010) Natural history and management of low-grade glioma in NF-1 children. J Neuro-Oncol 100:199–207. https://doi.org/10.1007/s11060-010-0159-z
Shofty B, Constantini S, Bokstein F, Ram Z, Ben-Sira L, Freedman S, Vainer G, Kesler A (2014) Optic pathway gliomas in adults. Neurosurgery 74:273–280. https://doi.org/10.1227/NEU.0000000000000257
Schindera C, Wingeier K, Goeggel Simonetti B, Diepold M, Nauer CB, Fleischhauer J, Steinlin M (2011) Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas? Childs Nerv Syst 27:2107–2111. https://doi.org/10.1007/s00381-011-1554-2
Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, Thakker N, Evans DG (2011) A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 48:256–260. https://doi.org/10.1136/jmg.2010.081760
Hutter S, Piro RM, Waszak SM, Kehrer-Sawatzki H, Friedrich RE, Lassaletta A, Witt O, Korbel JO, Lichter P, Schuhmann MU, Pfister SM, Tabori U, Mautner VF, Jones DTW (2016) No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Hum Genet 135:469–475. https://doi.org/10.1007/s00439-016-1646-x
Ahn Y, Cho BK, Kim SK, Chung YN, Lee CS, Kim IH, Yang SW, Kim HS, Kim HJ, Jung HW, Wang KC (2006) Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst 22:1136–1142
Lee AG (2007) Neuroophthalmological management of optic pathway gliomas. Neurosurg Focus 23:E1
Shofty B, Ben-Sira L, Freedman S, Yalon M, Dvir R, Weintraub M, Toledano H, Constantini S, Kesler A (2011) Visual outcome following chemotherapy for progressive optic pathway gliomas. Pediatr Blood Cancer 57:481–485. https://doi.org/10.1002/pbc.22967
Allen JC (2000) Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg 32:154–162. https://doi.org/10.1159/000028922
Dodge HW (1958) Gliomas of the optic nerves. AMA Arch Neur Psychiatry 79:607–621. https://doi.org/10.1001/archneurpsyc.1958.02340060003001
Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T, Benson C, Walker D, PLAN Study Group (2008) Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 81:761–766. https://doi.org/10.1259/bjr/65246351
McCullough DC, Epstein F (1985) Optic pathway tumors. A review with proposals for clinical staging. Cancer 56:1789–1791. https://doi.org/10.1002/1097-0142(19851001)56:7+<1789::aid-cncr2820561312>3.0.co;2-y
Shofty B, Weizman L, Joskowicz L, Constantini S, Kesler A, Ben-Bashat D, Yalon M, Dvir R, Freedman S, Roth J, Ben-Sira L (2011) MRI internal segmentation of optic pathway gliomas: clinical implementation of a novel algorithm. Childs Nerv Syst 27:1265–1272. https://doi.org/10.1007/s00381-011-1436-7
Shofty B, Mauda-Havakuk M, Weizman L, Constantini S, Ben-Bashat D, Dvir R, Pratt LT, Joskowicz L, Kesler A, Yalon M, Ravid L, Ben-Sira L (2015) The effect of chemotherapy on optic pathway gliomas and their sub-components: a volumetric MR analysis study. Pediatr Blood Cancer 62:1353–1359. https://doi.org/10.1002/pbc.25480
Weizman L, Ben Sira L, Joskowicz L, Constantini S, Precel R, Shofty B, Ben Bashat D (2012) Automatic segmentation, internal classification, and follow-up of optic pathway gliomas in MRI. Med Image Anal 16:177–188. https://doi.org/10.1016/j.media.2011.07.001
Hollander MD, FitzPatrick M, O’Connor SG et al (1999) Optic gliomas. Radiol Clin N Am 37(59–71):ix–71. https://doi.org/10.1016/s0033-8389(05)70078-6
Peyster RG, Hoover ED, Hershey BL, Haskin ME (1983) High-resolution CT of lesions of the optic nerve. AJR Am J Roentgenol 140:869–874. https://doi.org/10.2214/ajr.140.5.869
Shofty B, Ben-Sira L, Constantini S, Freedman S, Kesler A (2012) Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. Am J Neuroradiol 33:366–369. https://doi.org/10.3174/ajnr.A2779
Lober RM, Guzman R, Cheshier SH, Fredrick DR, Edwards MSB, Yeom KW (2012) Application of diffusion tensor tractography in pediatric optic pathway glioma. J Neurosurg Pediatr 10:273–280. https://doi.org/10.3171/2012.7.PEDS1270
Filippi CG, Bos A, Nickerson JP, Salmela MB, Koski CJ, Cauley KA (2012) Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3T in children with neurofibromatosis type I (NF-1). Pediatr Radiol 42:168–174. https://doi.org/10.1007/s00247-011-2216-y
de Blank PM, Berman JI, Liu GT et al (2013) Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro-oncology 15:1088–1095. https://doi.org/10.1093/neuonc/not068
Weizman L, Joskowicz L, Ben-Sira L, et al (2011) Longitudinal assessment of brain tumors using a repeatable prior-based segmentation. In: Proceedings - International Symposium on Biomedical Imaging
Avery RA, Bouffet E, Packer RJ, Reginald A (2013) Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas. Invest Ophthalmol Vis Sci 54:1034–1038. https://doi.org/10.1167/iovs.12-11385
Chang L, El-Dairi MA, Frempong TA et al (2010) Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS 14:511–517. https://doi.org/10.1016/j.jaapos.2010.08.014
Avery RA, Liu GT, Fisher MJ et al (2011) Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 151:542–549.e2. https://doi.org/10.1016/j.ajo.2010.08.046
Taylor M, Couto-Silva A-C, Adan L, Trivin C, Sainte-Rose C, Zerah M, Valteau-Couanet D, Doz F, Chalumeau M, Brauner R (2012) Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J Pediatr 161:855–863. https://doi.org/10.1016/j.jpeds.2012.05.014
Cnossen MH, Stam EN, Cooiman LC et al (1997) Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100:667–670
Komotar RJ, Burger PC, Carson BS, Brem H, Olivi A, Goldthwaite PT, Tihan T (2004) Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery 54:72–79; discussion 79-80. https://doi.org/10.1227/01.neu.0000097266.89676.25
Amatya VJ, Akazawa R, Sumimoto Y, Takeshima Y, Inai K (2009) Clinicopathological and immunohistochemical features of three pilomyxoid astrocytomas: comparative study with 11 pilocytic astrocytomas. Pathol Int 59:80–85. https://doi.org/10.1111/j.1440-1827.2008.02332.x
Zoeller GK, Brathwaite CD, Sandberg DI (2010) Malignant transformation of an optic pathway glioma without prior radiation therapy. J Neurosurg Pediatr 5:507–510. https://doi.org/10.3171/2009.12.PEDS09173
Piccirilli M, Lenzi J, Delfinis C, Trasimeni G, Salvati M, Raco A (2006) Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature. Childs Nerv Syst 22:1332–1337
Rozen WM, Joseph S, Lo PA (2008) Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg 44:324–328. https://doi.org/10.1159/000134925
King A, Listernick R, Charrow J et al (2003) Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 122:95–99
Kinori M, Armarnik S, Listernick R, Charrow J, Zeid JL (2020) Neurofibromatosis type 1 associated optic pathway glioma in children - a follow up of 10 years or more. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2020.03.053
Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW, Walter AW, Kuttesch JF, Muhlbauer M, Kun LE (1995) Low-grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 83:67–71. https://doi.org/10.3171/jns.1995.83.1.0067
Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17:4790–4798. https://doi.org/10.1158/1078-0432.ccr-11-0034
Astrup J (2003) Natural history and clinical management of optic pathway glioma. Br J Neurosurg 17:327–335. https://doi.org/10.1080/02688690310001601216
Fouladi M, Wallace D, Langston JW, Mulhern R, Rose SR, Gajjar A, Sanford RA, Merchant TE, Jenkins JJ, Kun LE, Heideman RL (2003) Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 97:1084–1092. https://doi.org/10.1002/cncr.11119
Shofty B, Ben-Sira L, Kesler A, Constantini S (2015) Optic pathway gliomas. In: Advances and technical standards in neurosurgery. pp 123–146
Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, St. Rose C, (on behalf of the CPN Paris 2011 Conference Consensus Group), van Meeteren AS, Carvalho A, van Damme A, Depreitere B, Gustavsson B, Due Tonnessen BJ, Bertozzi-Salamon AI, Brentrup A, Raybaud C, Jones C, Dufour C, Dorfer C, Sainte-Rose C, Malluci C, Hargrave D, Walker D, van Vuurden D, de Carli E, Bouffet E, van Calenbergh F, Frappaz D, Frassanito P, Goodrich J, Baechli H, Grill J, Ternier J, Cappelen J, Caird J, Pereira J, Riffaud L, Baroncini M, Walker M, Kieran M, Ozek M, Jabado N, Nysom K, Varlet P, Goodden J, Bertolini P, Perilongo G, Mercier P, Grundy R, Kortmann RD, Packer R, Pfister S, Constantini S, Sgouros S, Holm S, Czech T, Merchant T, Stokland T, Ridola V, Vandertop P (2013) A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro-oncology 15:462–468. https://doi.org/10.1093/neuonc/nos330
Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747–754. https://doi.org/10.3171/jns.1997.86.5.0747
Aquino VM, Fort DW, Kamen BA (1999) Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neuro-Oncol 41:255–259. https://doi.org/10.1023/a:1006149809479
Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U, Huang A, Bouffet E (2005) Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103:2636–2642. https://doi.org/10.1002/cncr.21091
Gururangan S, Fisher MJ, Allen JC et al (2007) Temozolomide in children with progressive low-grade glioma. Neuro-oncol 9:161–168. https://doi.org/10.1215/15228517-2006-030
Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37:569–583.e5. https://doi.org/10.1016/j.ccell.2020.03.011
Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW (2020) A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a neurofibromatosis clinical trials consortium study. Neuro-oncol. https://doi.org/10.1093/neuonc/noaa071
Yalon M, Rood B, MacDonald TJ et al (2013) A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer 60:71–76. https://doi.org/10.1002/pbc.24142
Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, Viskochil D, Knight P, Plotkin SR, Yohay K (2020) The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist. https://doi.org/10.1634/theoncologist.2020-0069
Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011–1022. https://doi.org/10.1016/S1470-2045(19)30277-3
Campagna M, Opocher E, Viscardi E, Calderone M, Severino SM, Cermakova I, Perilongo G (2010) Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer 55:1083–1088. https://doi.org/10.1002/pbc.22748
Fisher MJ, Balcer L, Gutmann DH et al (2010) Neurofibromatosis type I associated optic glioma visual outcomes following chemotherapy: an international multi-center retrospective analysis. Neuro-oncol 12:ii19–ii20
Leonard JR, Perry A, Rubin JB et al (2006) The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 67:1509–1512. https://doi.org/10.1212/01.wnl.0000240076.31298.47
Gnekow AK, Kandels D, van Tilburg C et al (2019) SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr 231:107–135. https://doi.org/10.1055/a-0889-8256
Shofty B, Ben-Sira L, Kesler A, Jallo G, Groves ML, Iyer RR, Lassaletta A, Tabori U, Bouffet E, Thomale UW, Hernáiz Driever P, Constantini S et al (2017) Isolated optic nerve gliomas: a multicenter historical cohort study. J Neurosurg Pediatr 20. https://doi.org/10.3171/2017.6.PEDS17107
Wisoff JH, Abbott R, Epstein F (1990) Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 73:661–667. https://doi.org/10.3171/jns.1990.73.5.0661
Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L (2001) Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 51:704–710. https://doi.org/10.1016/s0360-3016(01)01705-9
Steinbok P, Hentschel S, Almqvist P, Cochrane DD, Poskitt K (2002) Management of optic chiasmatic/hypothalamic astrocytomas in children. Can J Neurol Sci 29:132–138
Hoffman HJ, Soloniuk DS, Humphreys RP, Drake JM, Becker LE, de Lima BO, Piatt JH Jr (1993) Management and outcome of low-grade astrocytomas of the midline in children: a retrospective review. Neurosurgery 33:964–971. https://doi.org/10.1227/00006123-199312000-00002
Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M, Thorp N, Mallucci C (2014) The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr 13:1–12. https://doi.org/10.3171/2013.8.PEDS12546
Sawamura Y, Kamada K, Kamoshima Y, Yamaguchi S, Tajima T, Tsubaki J, Fujimaki T (2008) Role of surgery for optic pathway/hypothalamic astrocytomas in children. Neuro-oncol 10:725–733. https://doi.org/10.1215/15228517-2008-033
Hidalgo ET, Kvint S, Orillac C, North E, Dastagirzada Y, Chang JC, Addae G, Jennings TS, Snuderl M, Wisoff JH (2019) Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic/pilomyxoid optic pathway gliomas. J Neurosurg Pediatr 24:1–8. https://doi.org/10.3171/2019.2.PEDS18529
Millward CP, Perez Da Rosa S, Avula S et al (2015) The role of early intra-operative MRI in partial resection of optic pathway/hypothalamic gliomas in children. Childs Nerv Syst 31:2055–2062. https://doi.org/10.1007/s00381-015-2830-3
van Baarsen K, Roth J, Serova N, Packer RJ, Shofty B, Thomale UW, Cinalli G, Toledano H, Michowiz S, Constantini S (2018) Optic pathway-hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. J Neurosurg 129:1407–1415. https://doi.org/10.3171/2017.8.JNS163085
Gil Z, Beni-Adani L, Siomin V, Nagar H, Dvir R, Constantini S (2001) Ascites following ventriculoperitoneal shunting in children with chiasmatic-hypothalamic glioma. Childs Nerv Syst 17:395–398. https://doi.org/10.1007/s003810100460
Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27:3691–3697. https://doi.org/10.1200/JCO.2008.21.2738
Tsang DS, Murphy ES, Merchant TE (2017) Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys 99:642–651. https://doi.org/10.1016/j.ijrobp.2017.07.023
Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, Chi SN, Goumnerova L, Proctor M, Tarbell NJ, Marcus KJ, Pomeroy SL (2007) Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 68:932–938. https://doi.org/10.1212/01.wnl.0000257095.33125.48
Jenkin D, Angyalfi S, Becker L, Berry M, Buncic R, Chan H, Doherty M, Drake J, Greenberg M, Hendrick B, Hoffman H, Humphreys R, Weitzman S (1993) Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys 25:215–225. https://doi.org/10.1016/0360-3016(93)90342-s
Opocher E, Kremer LC, Da Dalt L et al (2006) Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 42:1807–1816
Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT, For the REiNS International Collaboration (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 81:S15–S24. https://doi.org/10.1212/01.wnl.0000435745.95155.b8
Gayre GS, Scott IU, Feuer W, Saunders TG, Siatkowski RM (2001) Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuroophthalmol 21:1–7
Dalla Via P, Opocher E, Pinello ML, Calderone M, Viscardi E, Clementi M, Battistella PA, Laverda AM, da Dalt L, Perilongo G (2007) Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro-oncol 9:430–437
Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S (2010) Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer S0959-8049(10):00259–00255. https://doi.org/10.1016/j.ejca.2010.03.028
Sharif S, Ferner R, Birch JM et al (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24:2570–2575. https://doi.org/10.1200/JCO.2005.03.8349
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare no conflict of interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Shofty, B., Ben Sira, L. & Constantini, S. Neurofibromatosis 1–associated optic pathway gliomas. Childs Nerv Syst 36, 2351–2361 (2020). https://doi.org/10.1007/s00381-020-04697-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00381-020-04697-1